{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:58Z","timestamp":1782208258471,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03588-2","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:36:37Z","timestamp":1776846997000},"page":"3014-3030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-6956","authenticated-orcid":false,"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-0146","authenticated-orcid":false,"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-4754","authenticated-orcid":false,"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2605-7200","authenticated-orcid":false,"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-9829","authenticated-orcid":false,"given":"Kaname","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-197X","authenticated-orcid":false,"given":"Zhihong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0227-8993","authenticated-orcid":false,"given":"Chie","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"3588_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","journal-title":"Cephalalgia"},{"key":"3588_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19:109\u201317. https:\/\/doi.org\/10.1038\/s41582-022-00763-1.","journal-title":"Nat Rev Neurol"},{"key":"3588_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44:8\u201319. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04004.x.","journal-title":"Headache"},{"key":"3588_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1701015.x.","journal-title":"Cephalalgia"},{"key":"3588_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945\u201355. https:\/\/doi.org\/10.1080\/03007995.2021.1971179.","journal-title":"Curr Med Res Opin"},{"key":"3588_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, Ishii R, Hamakawa M, Tanizawa Y, et al. The impact of migraine on the whole life course of patients: results from the OVERCOME (Japan) 2nd study. Neurol Ther. 2025;14:335\u201356. https:\/\/doi.org\/10.1007\/s40120-024-00690-x.","journal-title":"Neurol Ther"},{"key":"3588_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, et al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Neurol Ther. 2022;11:205\u201322. https:\/\/doi.org\/10.1007\/s40120-021-00305-9.","journal-title":"Neurol Ther"},{"key":"3588_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"3588_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener H-C, Ashina M, Al-Khazali HM, Ashina S, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024;44:03331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735.","journal-title":"Cephalalgia"},{"key":"3588_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ncn3.70042","volume":"13","author":"N Araki","year":"2025","unstructured":"Araki N, Takeshima T, Igarashi H, Shimizu T, Shibata M, Tatsumoto M, et al. Clinical practice guideline for headache disorders 2021. Neurol Clin Neurosci. 2025;13:389\u2013407. https:\/\/doi.org\/10.1111\/ncn3.70042.","journal-title":"Neurol Clin Neurosci"},{"key":"3588_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501\u201314. https:\/\/doi.org\/10.1038\/s41582-021-00509-5.","journal-title":"Nat Rev Neurol"},{"key":"3588_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/head.14053","volume":"61","author":"AK Kawata","year":"2021","unstructured":"Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache. 2021;61:438\u201354. https:\/\/doi.org\/10.1111\/head.14053.","journal-title":"Headache"},{"key":"3588_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470\u201385. https:\/\/doi.org\/10.1177\/0333102416678382.","journal-title":"Cephalalgia"},{"key":"3588_CR14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39:1518\u201334. https:\/\/doi.org\/10.1177\/0333102419851855.","journal-title":"Cephalalgia"},{"key":"3588_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including Galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adher. 2022;16:821\u201339. https:\/\/doi.org\/10.2147\/PPA.S346660.","journal-title":"Patient Prefer Adher"},{"key":"3588_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"key":"3588_CR17","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"key":"3588_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of Galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia"},{"key":"3588_CR19","unstructured":"Pharmaceuticals and Medical Devices Agency. List of approved drugs April 2004 to March 2025: Pharmaceuticals and Medical Devices Agency; 2024 [cited October 09, 2025]. Available from: https:\/\/www.pmda.go.jp\/files\/000274881.pdf."},{"key":"3588_CR20","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for promoting the optimal use of galcanezumab (genetically recombinant) preparations [in Japanese]. Tokyo: The Japanese Headache Society; 2021 [cited May 08, 2025]. Available from: https:\/\/www.mhlw.go.jp\/content\/12404000\/000768564.pdf."},{"key":"3588_CR21","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for promoting the optimal use of Fremanezumab (genetically recombinant) preparations [in Japanese]. Tokyo: The Japanese Headache Society; 2021 [cited May 08, 2025]. Available from: https:\/\/www.jhsnet.net\/GUIDELINE\/CGRP\/6.pdf."},{"key":"3588_CR22","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for promoting the optimal use of Erenumab (genetically recombinant) preparations [in Japanese]. Tokyo: The Japanese Headache Society; 2021 [cited May 08, 2025]. Available from: https:\/\/www.jhsnet.net\/GUIDELINE\/CGRP\/8.pdf."},{"key":"3588_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, et al. Real-world evidence of Galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022;22:512. https:\/\/doi.org\/10.1186\/s12883-022-03041-1.","journal-title":"BMC Neurol"},{"key":"3588_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231177649","volume":"43","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia. 2023;43:3331024231177649. https:\/\/doi.org\/10.1177\/03331024231177649.","journal-title":"Cephalalgia"},{"key":"3588_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125751","volume":"481","author":"S Imai","year":"2026","unstructured":"Imai S, Ihara K, Takahashi N, Ohtani S, Watanabe N, Iba C, et al. A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine. J Neurol Sci. 2026;481:125751. https:\/\/doi.org\/10.1016\/j.jns.2026.125751.","journal-title":"J Neurol Sci"},{"key":"3588_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/head.15045","author":"RB Lipton","year":"2025","unstructured":"Lipton RB, Lainez MJA, Ahmed Z, Vallarino C, Novick D, Vincent M, et al. Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: results from the TRIUMPH study. Headache. 2025. https:\/\/doi.org\/10.1111\/head.15045.","journal-title":"Headache"},{"key":"3588_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01737-y","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Watanabe N, Takemura R, Takahashi N, Miyazaki N, et al. CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain. 2024;25:39. https:\/\/doi.org\/10.1186\/s10194-024-01737-y.","journal-title":"J Headache Pain"},{"key":"3588_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40:1026\u201344. https:\/\/doi.org\/10.1177\/0333102420941839.","journal-title":"Cephalalgia"},{"key":"3588_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19:107\u201314. https:\/\/doi.org\/10.1046\/j.1468-2982.1999.019002107.x.","journal-title":"Cephalalgia"},{"key":"3588_CR30","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/wnl.56.suppl_1.s20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20\u20138. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20.","journal-title":"Neurology"},{"key":"3588_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84:422\u201335. https:\/\/doi.org\/10.1016\/S0025-6196(11)60561-2.","journal-title":"Mayo Clin Proc"},{"issue":"suppl1","key":"3588_CR32","volume":"68","author":"D Buse","year":"2007","unstructured":"Buse D, Bigal MB, Rupnow M, Reed M, Serrano D, Lipton R. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks. Neurology. 2007;68(suppl1):A89.","journal-title":"Neurology"},{"key":"3588_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr., Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963\u201374. https:\/\/doi.org\/10.1023\/a:1026119331193.","journal-title":"Qual Life Res"},{"key":"3588_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998;38:295\u2013302. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3804295.x.","journal-title":"Headache"},{"key":"3588_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"key":"3588_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/head.14460","volume":"63","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Sandoe CH, Ford JH, Hand AL, Jedynak JP, et al. Changes in migraine interictal burden following treatment with galcanezumab: results from a phase III randomized, placebo-controlled study. Headache. 2023;63:683\u201391. https:\/\/doi.org\/10.1111\/head.14460.","journal-title":"Headache"},{"key":"3588_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01322-7","volume":"22","author":"R Okonkwo","year":"2021","unstructured":"Okonkwo R, Tockhorn-Heidenreich A, Stroud C, Paget MA, Matharu MS, Tassorelli C. Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study. J Headache Pain. 2021;22:113. https:\/\/doi.org\/10.1186\/s10194-021-01322-7.","journal-title":"J Headache Pain"},{"key":"3588_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-01952-1","volume":"26","author":"W Rattanawong","year":"2025","unstructured":"Rattanawong W, Anukoolwittaya P, Hiransuthikul A, Pongpitakmetha T, Trisataya A, Thanprasertsuk S, et al. Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation. J Headache Pain. 2025;26:13. https:\/\/doi.org\/10.1186\/s10194-025-01952-1.","journal-title":"J Headache Pain"},{"key":"3588_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03521-y","volume":"24","author":"M Shibata","year":"2024","unstructured":"Shibata M, Fujita K, Hoshino E, Minami K, Koizumi K, Okada S, et al. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. BMC Neurol. 2024;24:32. https:\/\/doi.org\/10.1186\/s12883-023-03521-y.","journal-title":"BMC Neurol"},{"key":"3588_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1.","journal-title":"J Headache Pain"},{"key":"3588_CR41","doi-asserted-by":"publisher","first-page":"590","DOI":"10.50860\/jjho.49.3_590","volume":"49","author":"N Sanno","year":"2023","unstructured":"Sanno N, Basugi A, Sakai F. Efficacy and safety of galcanezumab for migraine prevention: 6 months experience in a headache clinic. Jpn J Headache. 2023;49:590\u20133. https:\/\/doi.org\/10.50860\/jjho.49.3_590.","journal-title":"Jpn J Headache"},{"key":"3588_CR42","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1212\/WNL.0000000000007856","volume":"93","author":"JH Ford","year":"2019","unstructured":"Ford JH, Ayer DW, Zhang Q, Carter JN, Leroux E, Skljarevski V, et al. Two randomized migraine studies of galcanezumab: effects on patient functioning and disability. Neurology. 2019;93:e508\u201317. https:\/\/doi.org\/10.1212\/WNL.0000000000007856.","journal-title":"Neurology"},{"key":"3588_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01485-x","volume":"23","author":"F Pistoia","year":"2022","unstructured":"Pistoia F, Salfi F, Saporito G, Ornello R, Frattale I, D\u2019Aurizio G, et al. Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities. J Headache Pain. 2022;23:110. https:\/\/doi.org\/10.1186\/s10194-022-01485-x.","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"3588_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10072-014-1780-y","volume":"35","author":"M Leonardi","year":"2014","unstructured":"Leonardi M. Higher burden of migraine compared to other neurological conditions: results from a cross-sectional study. Neurol Sci. 2014;35(Suppl 1):149\u201352. https:\/\/doi.org\/10.1007\/s10072-014-1780-y.","journal-title":"Neurol Sci"},{"key":"3588_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02079-z","volume":"26","author":"T Takizawa","year":"2025","unstructured":"Takizawa T, Danno D, Ishii R, Suzuki S, Miura M, Tanizawa Y, et al. The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study. J Headache Pain. 2025;26:140. https:\/\/doi.org\/10.1186\/s10194-025-02079-z.","journal-title":"J Headache Pain"},{"key":"3588_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/clep.S178723","volume":"11","author":"M Sharma","year":"2019","unstructured":"Sharma M, Nazareth I, Petersen I. Observational studies of treatment effectiveness: worthwhile or worthless? Clin Epidemiol. 2019;11:35\u201342. https:\/\/doi.org\/10.2147\/clep.S178723.","journal-title":"Clin Epidemiol"},{"key":"3588_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.hfc.2012.09.007","volume":"9","author":"MA Hlatky","year":"2013","unstructured":"Hlatky MA, Winkelmayer WC, Setoguchi S. Epidemiologic and statistical methods for comparative effectiveness research. Heart Fail Clin. 2013;9:29\u201336. https:\/\/doi.org\/10.1016\/j.hfc.2012.09.007.","journal-title":"Heart Fail Clin"},{"key":"3588_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"key":"3588_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","volume":"59","author":"T Sturmer","year":"2020","unstructured":"Sturmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. Rheumatology (Oxford). 2020;59:14\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/kez320.","journal-title":"Rheumatology (Oxford)"},{"key":"3588_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030734","author":"MK Kang","year":"2025","unstructured":"Kang MK, Sohn JH, Cha MJ, Kim YH, Hong Y, Im HJ, et al. One-year compliance after calcitonin gene-related peptide monoclonal antibody therapy for migraine patients in a real-world setting: a multicenter cross-sectional study. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14030734.","journal-title":"J Clin Med"},{"key":"3588_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0498-8","volume":"19","author":"EK Seng","year":"2015","unstructured":"Seng EK, Rains JA, Nicholson RA, Lipton RB. Improving medication adherence in migraine treatment. Curr Pain Headache Rep. 2015;19:24. https:\/\/doi.org\/10.1007\/s11916-015-0498-8.","journal-title":"Curr Pain Headache Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03588-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:23:04Z","timestamp":1782206584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03588-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3588"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03588-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takao Takeshima served on the speakers\u2019 bureau for Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd.; received research funding\/collaborative research expenses from AbbVie G.K., Amgen K.K., Eli Lilly Japan K.K., Eisai Co., Ltd., Lundbeck Japan K.K., and Pfizer Japan Inc.; and served as an advisor to Hedgehog MedTech, Inc., Sawai Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Yasuhiko Matsumori received personal consultancy fees from Amgen K.K., Astellas Pharma Inc., BioPharma K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Daisuke Danno received advisory fees from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Lundbeck; and honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Tsubasa Takizawa is a consultant\/adviser and\/or serves on an advisory board for Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., AbbVie G.K., and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., and Sawai Pharmaceutical Co., Ltd., a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura & Co., outside the submitted work. Kaname Ueda, Zhihong Cai, Chie Hashimoto, and Hideaki Katagiri are employees of Eli Lilly Japan K.K. and may own stock\/stock options of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Each participating site in Japan obtained study approval from the site-specific ethics review committee. This study was conducted in accordance with the Declaration of Helsinki (1964) and its later amendments and Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. All participants provided informed consent and agreed to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}